newsfilter
← Latest News
Business Wire·

Niagen Bioscience Announces Start-Up Agreement With Mass General Brigham (MGB) Investigators For First-Of-Its-Kind Healthy Aging Clinical Trial

Proposed multi-year, randomized, placebo-controlled prevention trial would evaluate Niagen (patented nicotinamide riboside, or NR) supplementation across major clinical outcomes and healthy aging-related measures in